Creso Pharma and Apotheke Dr. Hysek partner to import MDMA and psilocybin treatments to Australia  
    Creso Pharma trains sights on lucrative Australian market following change in licensing process  
    Creso Pharma reports strong sales, licence extensions for Canadian subsidiary Mernova  
    Creso Pharma raises A$2.5 million, streamlines balance sheet for growth strategy  
    Creso Pharma strengthens market position on completing Health House International acquisition  
    Creso Pharma hones in on pivotal Asian markets with Singapore and South Korea distribution deals  
    Creso Pharma has eyes on multi-million dollar functional mushroom product market  
    Creso Pharma gains Supreme Court green light for Health House acquisition  
    Creso Pharma's subsidiary Halucenex demonstrates potential of psilocybin to treat PTSD  
    Creso Pharma subsidiary secures new purchase orders and expands into Alberta  
    Creso Pharma has strong foundation for growth across multiple verticals  
    Creso Pharma boosts balance sheet through A$2.5 million convertible note issue  
    Creso Pharma boosts finances for marketing push into US, psilocybin trial, with $2 million placement  
    Creso Pharma has strong foundation for growth across multiple verticals in 2023  
    Creso Pharma looks to bring psilocybin to Australian market after TGA downgrade  
    Creso Pharma looks to acquire baby product company Abby and Finn; to streamline finance structure  
    Creso Pharma expands Canadian footprint; secures largest purchase order ever  
    Creso Pharma subsidiary Mernova to launch seven new products in Canada  
    Creso Pharma draws additional A$500,000 on funding facility; shareholders approve A$2 million in placement participation by directors  
    Creso Pharma subsidiary Halucenex doses first patient in Lucenex Phase 2 trial targeting PTSD  
    Creso Pharma taps Peter Hatfull for board seat  
    Creso Pharma starts to unlock Health House revenue streams and expansion initiatives  
    Creso Pharma welcomes news it is “no longer the subject of investigation” by ASIC  
    Creso Pharma inks scheme implementation deed to acquire Health House International  
    Creso Pharma welcomes Canadian subsidiary’s large purchase orders from Saskatchewan cannabis co-operative  
    Creso Pharma US subsidiary Sierra Sage Herbs expands Green Goo into Canada  
    Creso Pharma’s Mernova awarded amended Health Canada sales licence  
    Creso Pharma to raise $7.6 million through an issue of two separate convertible notes  
    Creso Pharma to rebrand as Melodiol Global Health to better represent its international ambitions  
    Creso Pharma US subsidiary Sierra Sage Herbs LLC inks wholesale agreement with accelerate360  
    Creso Pharma accelerates growth strategy with director appointments, board transition and rebranding  
    Creso Pharma to start psilocybin clinical trials into PTSD via wholly-owned Halucenex  
    Creso Pharma subsidiary Mernova expands Canadian medicinal cannabis footprint  
    Creso Pharma subsidiary Mernova Medicinal broadens Canadian footprint with provincial partnerships  
    Creso Pharma psychedelics subsidiary Halucenex kicks off Phase 2 of psilocybin PTSD clinical trial  
    Creso Pharma advances Health House International transaction  
    Creso Pharma subsidiary secures US$214,000 purchase order from Walmart  
    Creso Pharma launches into US CBD market on completing Sierra Sage Herbs acquisition  
    Creso Pharma subsidiary Halucenex poised to begin psilocybin PTSD clinical trial following Health Canada update  
    Creso Pharma subsidiary appoints renowned sports performance coach as brand ambassador ahead of product launch  
    Creso Pharma’s Canadian subsidiary generates revenue of $3 million year-to-date  
    Creso Pharma raising A$7 million for further US expansion  
    Creso Pharma inks non-binding term sheet to acquire international pharmaceutical distributor Health House  
    Creso Pharma target Sierra Sage Herbs secures private label manufacturing agreement with US online retailer  
    Creso Pharma subsidiary Mernova delivers new Ontario cannabis sales  
    Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials  
    Creso Pharma's Canadian subsidiary ImpACTIVE appoints three new brand ambassadors ahead of launch  
    Creso Pharma secures LOI to commercialise anibidiol® products targeting pet health in South Korea  
    Creso Pharma inks agreement to launch Sierra Sage Herbs pet care products in Singapore  
    Creso Pharma agreement sees it spread wings in Taiwan’s growing animal health market  
    Creso Pharma’s Canadian subsidiary Mernova lands first purchase order for Ritual Gold vaporiser products  
    Creso Pharma subsidiary receives first order for new strains and takes third place in Cannabis Cup  
    Creso Pharma’s psychedelics company signs psilocybin supply agreement  
    Creso Pharma eyes potential pathway into Australian body care market through Dr Pickles agreement, shares higher  
    Creso Pharma’s psychedelics subsidiary Halucenex secures psilocybe cubensis import permit from Health Canada  
    Creso Pharma acquisition target expands US footprint  
    Creso Pharma welcomes passing of Cannabis Act in US House of Representatives  
    Creso Pharma secures LOI for commercialisation with Laboratorios Brouwer to broaden LATAM market sales  
    Creso Pharma hits major mushroom milestones  
    Creso Pharma subsidiary Mernova achieves market milestone and improves crop yield  
    Creso Pharma set to unlock US product sales and manufacturing with Sierra Sage Herbs  
    Creso Pharma’s psychedelics company cleared to start clinical trials  
    Creso Pharma secures commitments to raise $5 million, plans to grow US footprint  
    Creso Pharma set to launch new range of vaporisers as it expands its footprint in North America  
    Creso Pharma’s acquisition of Sierra Sage Herbs see multiple product launches on the horizon  
    Creso Pharma to develop hemp-based lozenge product and expand international opportunities  
    Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors  
    Creso Pharma pushes into US CBD market with revenue-generating acquisition